Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Valsartan
    • 1.4.3 Irbesartan
    • 1.4.4 Candesartan Cilexetil
    • 1.4.5 Eprosartan
    • 1.4.6 Irbesartan
    • 1.4.7 Telmisartan
    • 1.4.8 losartan
    • 1.4.9 Olmesartan Medoxomil
    • 1.4.10 Allisartan isoproxil
  • 1.5 Market by Application
    • 1.5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application: 2020 VS 2026
    • 1.5.2 High Blood Pressure
    • 1.5.3 Congestive Heart Failure
    • 1.5.4 Left Ventricular Hypertrophy
    • 1.5.5 Atherosclerosis
    • 1.5.6 Other
  • 1.6 Coronavirus Disease 2019 (Covid-19): Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry
      • 1.6.1.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Non-Peptide Drugs of Angiotensin II Receptor Antagonist Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Perspective (2015-2026)
  • 2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Growth Trends by Regions
    • 2.2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Share by Regions (2015-2020)
    • 2.2.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Market Size
    • 3.1.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Revenue (2015-2020)
    • 3.1.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio
    • 3.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2019
  • 3.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players Head office and Area Served
  • 3.4 Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Solution and Service
  • 3.5 Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Type (2015-2020)
  • 4.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Type (2021-2026)

5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Breakdown Data by Application (2015-2026)

  • 5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
  • 5.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
  • 6.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in North America (2019-2020)
  • 6.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
  • 6.4 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
  • 7.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Europe (2019-2020)
  • 7.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
  • 7.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

8 China

  • 8.1 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
  • 8.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in China (2019-2020)
  • 8.3 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
  • 8.4 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
  • 9.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Japan (2019-2020)
  • 9.3 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
  • 9.4 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
  • 10.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

11 India

  • 11.1 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
  • 11.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in India (2019-2020)
  • 11.3 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
  • 11.4 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
  • 12.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
  • 12.4 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Pfizer
    • 13.1.1 Pfizer Company Details
    • 13.1.2 Pfizer Business Overview and Its Total Revenue
    • 13.1.3 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 13.1.4 Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020))
    • 13.1.5 Pfizer Recent Development
  • 13.2 Novartis
    • 13.2.1 Novartis Company Details
    • 13.2.2 Novartis Business Overview and Its Total Revenue
    • 13.2.3 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 13.2.4 Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 13.2.5 Novartis Recent Development
  • 13.3 Merck
    • 13.3.1 Merck Company Details
    • 13.3.2 Merck Business Overview and Its Total Revenue
    • 13.3.3 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 13.3.4 Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 13.3.5 Merck Recent Development
  • 13.4 AstraZeneca
    • 13.4.1 AstraZeneca Company Details
    • 13.4.2 AstraZeneca Business Overview and Its Total Revenue
    • 13.4.3 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 13.4.4 AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 13.4.5 AstraZeneca Recent Development
  • 13.5 Jhonson and Johnson
    • 13.5.1 Jhonson and Johnson Company Details
    • 13.5.2 Jhonson and Johnson Business Overview and Its Total Revenue
    • 13.5.3 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 13.5.4 Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 13.5.5 Jhonson and Johnson Recent Development
  • 13.6 Eli Lilly
    • 13.6.1 Eli Lilly Company Details
    • 13.6.2 Eli Lilly Business Overview and Its Total Revenue
    • 13.6.3 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 13.6.4 Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 13.6.5 Eli Lilly Recent Development
  • 13.7 Sanofi
    • 13.7.1 Sanofi Company Details
    • 13.7.2 Sanofi Business Overview and Its Total Revenue
    • 13.7.3 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 13.7.4 Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 13.7.5 Sanofi Recent Development
  • 13.8 Bristol-Myers Squibb
    • 13.8.1 Bristol-Myers Squibb Company Details
    • 13.8.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
    • 13.8.3 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 13.8.4 Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 13.8.5 Bristol-Myers Squibb Recent Development
  • 13.9 Bayer
    • 13.9.1 Bayer Company Details
    • 13.9.2 Bayer Business Overview and Its Total Revenue
    • 13.9.3 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 13.9.4 Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 13.9.5 Bayer Recent Development
  • 13.10 GSK
    • 13.10.1 GSK Company Details
    • 13.10.2 GSK Business Overview and Its Total Revenue
    • 13.10.3 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 13.10.4 GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 13.10.5 GSK Recent Development
  • 13.11 Teva Pharmaceutical
    • 10.11.1 Teva Pharmaceutical Company Details
    • 10.11.2 Teva Pharmaceutical Business Overview and Its Total Revenue
    • 10.11.3 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 10.11.4 Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 10.11.5 Teva Pharmaceutical Recent Development
  • 13.12 Shenzhen Salubris Pharmaceuticals
    • 10.12.1 Shenzhen Salubris Pharmaceuticals Company Details
    • 10.12.2 Shenzhen Salubris Pharmaceuticals Business Overview and Its Total Revenue
    • 10.12.3 Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 10.12.4 Shenzhen Salubris Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 10.12.5 Shenzhen Salubris Pharmaceuticals Recent Development
  • 13.13 Sun Pharmaceutical
    • 10.13.1 Sun Pharmaceutical Company Details
    • 10.13.2 Sun Pharmaceutical Business Overview and Its Total Revenue
    • 10.13.3 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 10.13.4 Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 10.13.5 Sun Pharmaceutical Recent Development
  • 13.14 Mylan
    • 10.14.1 Mylan Company Details
    • 10.14.2 Mylan Business Overview and Its Total Revenue
    • 10.14.3 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 10.14.4 Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 10.14.5 Mylan Recent Development
  • 13.15 Alembic Pharmaceuticals
    • 10.15.1 Alembic Pharmaceuticals Company Details
    • 10.15.2 Alembic Pharmaceuticals Business Overview and Its Total Revenue
    • 10.15.3 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 10.15.4 Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 10.15.5 Alembic Pharmaceuticals Recent Development
  • 13.16 Lupin
    • 10.16.1 Lupin Company Details
    • 10.16.2 Lupin Business Overview and Its Total Revenue
    • 10.16.3 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 10.16.4 Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 10.16.5 Lupin Recent Development
  • 13.17 Aurobindo Pharma
    • 10.17.1 Aurobindo Pharma Company Details
    • 10.17.2 Aurobindo Pharma Business Overview and Its Total Revenue
    • 10.17.3 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 10.17.4 Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 10.17.5 Aurobindo Pharma Recent Development
  • 13.18 Amneal Pharmaceuticals
    • 10.18.1 Amneal Pharmaceuticals Company Details
    • 10.18.2 Amneal Pharmaceuticals Business Overview and Its Total Revenue
    • 10.18.3 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 10.18.4 Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 10.18.5 Amneal Pharmaceuticals Recent Development
  • 13.19 Boehringer Ingelheim
    • 10.19.1 Boehringer Ingelheim Company Details
    • 10.19.2 Boehringer Ingelheim Business Overview and Its Total Revenue
    • 10.19.3 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
    • 10.19.4 Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
    • 10.19.5 Boehringer Ingelheim Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Non-Peptide Drugs of Angiotensin II Receptor Antagonist status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Non-Peptide Drugs of Angiotensin II Receptor Antagonist development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Pfizer
    Novartis
    Merck
    AstraZeneca
    Jhonson and Johnson
    Eli Lilly
    Sanofi
    Bristol-Myers Squibb
    Bayer
    GSK
    Teva Pharmaceutical
    Shenzhen Salubris Pharmaceuticals 
    Sun Pharmaceutical
    Mylan
    Alembic Pharmaceuticals
    Lupin
    Aurobindo Pharma
    Amneal Pharmaceuticals
    Boehringer Ingelheim

    Market segment by Type, the product can be split into
    Valsartan
    Irbesartan
    Candesartan Cilexetil
    Eprosartan
    Irbesartan
    Telmisartan
    losartan
    Olmesartan Medoxomil
    Allisartan isoproxil
    Market segment by Application, split into
    High Blood Pressure
    Congestive Heart Failure
    Left Ventricular Hypertrophy
    Atherosclerosis
    Other

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Non-Peptide Drugs of Angiotensin II Receptor Antagonist status, future forecast, growth opportunity, key market and key players.
    To present the Non-Peptide Drugs of Angiotensin II Receptor Antagonist development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Non-Peptide Drugs of Angiotensin II Receptor Antagonist are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now